Appendix 3G — Director's Options
August 6, 2020Investor updates
Imagion Biosystems has announced Appendix 3G — FY20 Director's Options. Download the announcement.
Appendix 3G — Performance Rights and Performance Options
August 6, 2020Investor updates
Imagion Biosystems has announced Appendix 3G — FY20 Performance Rights and Performance Options. Download the announcement.
Phase I Study Update: Submission for Ethics Approval Filed
August 5, 2020News,Investor updates
Imagion Biosystems is pleased to provide an update with regard to its plans to undertake a Phase I study of its first MagSense™ product for the detection of…
Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001
Imagion Biosystems Limited gives notice that, on 4 August 2020 the Company issued 112,111,111 fully paid ordinary shares (Shares) as well as 6,500,000…
Appendix 2A — IBXOA Options
August 4, 2020Investor updates
Imagion Biosystems Limited announces Appendix 2A — IBXOA Options. Read the announcement.
Appendix 2A — Fully Paid Ordinary Shares
August 4, 2020Investor updates
Imagion Biosystems Limited announces Appendix 2A — Fully Paid Ordinary Shares. Read the announcement.
Proposed Issue of Securities — IBXOA
August 4, 2020Investor updates
Imagion Biosystems Limited announces the proposed issue of 1,500,000 options expiring 28 April, 2023. Read the announcement.
Proposed Issue of Securities — IBX
August 4, 2020Investor updates
Imagion Biosystems Limited announces the proposed issue of 1,000,000 ordinary fully paid securities. Read the announcement.
Upcoming Release of Shares from Escrow
Imagion Biosystems Limited (ASX: IBX) (the Company) advises in accordance with Listing Rule 3.10A, that 2,500,000 Fully Paid Ordinary Shares will be…
Quarterly Activity Report and Appendix C
July 29, 2020News,Investor updates
Quarterly Activity Report – Period ending 30 June 2020 Q2 Highlights: Company announces plans for the Phase I first-in-human study to be undertaken in…